The delivery method showed promise in preventing the illness.
Mike Hollan
Advertisement
Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
Articles by Mike Hollan
Between tariffs, funding cuts, and changes at HHS, pharma is facing new challenges.
The AI company’s tech will be integrated with Microsoft Azure’s infrastructure.
The fundraising event will debut in Nashville this August.
The football player is speaking out about his experience living with and treating OAB.
Olympia Pharmaceuticals’ co-founders discuss how they’re pivoting in light of FDA’s decision.
Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.
Customers will be able to access prescription services through the NovoCare Pharmacy.
The actor suffers from the ear condition after an accident on set during the filming of Star Trek.
People on both Medicaid and Medicare struggle navigating both services.
New rules places upon the pharma industry will have a significant impact on how investors view the industry.
The results show many people start dropping the medication by the first year of using it.
Williams will serve as entrepreneur-in-chief and will help groups in the program with mentorship.
New technologies and external factors are forcing companies to rethink financial planning and analysis.
The drug-maker cited concerns over deceptive marketing and the selling of compounded GLP-1 medications.
This is the latest partnership for PharmaJet.
Members will have access to oncology specialists.
Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey behind his lifelong advocacy for mentorship—and, cliché or not, the lasting power of “you get what you give.”
The study is part of a larger movement analyzing the health habits of people taking these medications.
The companies are working together to make it easier for companies to offer health plans that include these medications.
The bill is in line with comments RFK Jr. has made about this form of advertising.
The agent, named eVa, can replace multiple tools for marketers.
The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.
The project is being developed in partnership with Insulet Corporation.
The group is made up of lung cancer patients and survivors.
Phenomix and the Mayo Clinic partnered to test the effectiveness of the MyPhenome test.
The move is part of a larger strategy to focus the companies in this group for greater collaborative work.
The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face.
The Care Collective will provide marketing opportunities for tv, streaming, and digital platforms.
While the medications may reduce diet, the best results will be achieved by building healthy habits alongside the drugs.
Advertisement